{{Rsnum
|rsid=2056387
|Gene=RYR2
|Chromosome=1
|position=237760812
|Orientation=plus
|GMAF=0.2443
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=RYR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 9.8 | 42.0 | 48.2
| HCB | 0.7 | 7.3 | 92.0
| JPT | 0.0 | 6.2 | 93.8
| YRI | 10.9 | 49.7 | 39.5
| ASW | 8.8 | 50.9 | 40.4
| CHB | 0.7 | 7.3 | 92.0
| CHD | 0.0 | 9.2 | 90.8
| GIH | 5.9 | 24.8 | 69.3
| LWK | 10.9 | 42.7 | 46.4
| MEX | 13.8 | 43.1 | 43.1
| MKK | 9.7 | 43.9 | 46.5
| TSI | 8.8 | 44.1 | 47.1
| HapMapRevision=28
}}Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.{{PMID|17903301|OA=1
}}

{{PMID Auto
|PMID=17903305
|Title=A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}